List of Excipients in API pivekimab sunirine-pvzy
✉ Email this page to a colleague
Detailed excipient profiles for pivekimab sunirine-pvzy
Excipient focus: METHIONINE
pivekimab sunirine-pvzy drug variants containing METHIONINE
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | pivekimab sunirine-pvzy | 0074-0282 |
| >Company | >Ingredient | >NDC |
pivekimab sunirine-pvzy drug variants not containing METHIONINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 20
pivekimab sunirine-pvzy drug variants containing POLYSORBATE 20
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | pivekimab sunirine-pvzy | 0074-0282 |
| >Company | >Ingredient | >NDC |
pivekimab sunirine-pvzy drug variants not containing POLYSORBATE 20
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM HYDROXIDE
pivekimab sunirine-pvzy drug variants containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | pivekimab sunirine-pvzy | 0074-0282 |
| >Company | >Ingredient | >NDC |
pivekimab sunirine-pvzy drug variants not containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM METABISULFITE
pivekimab sunirine-pvzy drug variants containing SODIUM METABISULFITE
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | pivekimab sunirine-pvzy | 0074-0282 |
| >Company | >Ingredient | >NDC |
pivekimab sunirine-pvzy drug variants not containing SODIUM METABISULFITE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SUCCINIC ACID
pivekimab sunirine-pvzy drug variants containing SUCCINIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | pivekimab sunirine-pvzy | 0074-0282 |
| >Company | >Ingredient | >NDC |
pivekimab sunirine-pvzy drug variants not containing SUCCINIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TREHALOSE
pivekimab sunirine-pvzy drug variants containing TREHALOSE
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | pivekimab sunirine-pvzy | 0074-0282 |
| >Company | >Ingredient | >NDC |
pivekimab sunirine-pvzy drug variants not containing TREHALOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
pivekimab sunirine-pvzy drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | pivekimab sunirine-pvzy | 0074-0282 |
| >Company | >Ingredient | >NDC |
pivekimab sunirine-pvzy drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
